Safety Center

Review your GLP-1 provider's public record before you enroll

Before you start a GLP-1, check three things: the program's FDA warning-letter record, the pharmacy that makes your medicine, and the side effects of your exact drug and dose.

Our warning tracker documents 16 sourced FDA letters dated across 2025 and 2026. It is a curated subset, not a count of every agency action.

No provider pays to appear in these resources.

Check a program before you pay

Warning letters, the pharmacy behind your medicine and court cases.

Check dated complaint and rating records alongside these checks. Individual reports do not establish clinical quality or a failure rate.

Side effects by medicine

The percentages come from separate trials with different doses and populations. They are not a head-to-head safety ranking or a prediction of your symptoms. Open each guide for the table and prescribing-information source.

Before you start

Three things to do before you start

1

Check the program

Use our Warning & Transparency Checker to review sourced FDA letters and claim-level pharmacy details. "Unknown" means we found nothing either way.

Confirm the current pharmacy and prescriber with the program before you enroll.

2

Start low, go slow

Follow the dose schedule you are prescribed. Moving up too fast makes stomach side effects worse. Use our dosing timeline tool.

3

Report problems

Report adverse reactions to FDA MedWatch and your prescribing provider immediately.

Independent Clinical Perspective

What the doctors say about GLP-1 safety

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“Americans should be confident that the prescription drugs they take are safe. By strengthening oversight of imported APIs and cracking down on illegal drugs entering the U.S., we are taking aggressive action to protect consumers from poor-quality or dangerous GLP-1 drugs.”
Marty Makary, MD, MPH, FDA Commissioner
U.S. Food and Drug Administration
Announcing the FDA 'Green List' to block illegally imported GLP-1 active ingredients used in compounding.
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
Jacqueline M. Stephens, PhD, FTOS, President, The Obesity Society
The Obesity Society
Official Obesity Society statement on compounded GLP-1 medications.
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
Marc-Andre Cornier, MD, endocrinologist; immediate past president of The Obesity Society
Medical University of South Carolina
On why some online/telehealth GLP-1 programs fall short of a proper clinical standard of care.

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.